The purpose of this study is to evaluate the safety and effectiveness of the combination of two drugs — vorinostat and etoposide — in children with malignant solid tumors that continue to grow despite standard therapy or for which no standard therapy exists.
Etoposide is a commonly used chemotherapy drug. Vorinostat is approved to treat a certain type of lymphoma in adults, but its use in children is considered investigational. Vorinostat is a capsule that is taken by mouth; etoposide is given intravenously (by vein).
Vorinostat is a drug called a histone deacetylase (HDAC) inhibitor. It prevents cancer cells from reproducing by interfering with certain signaling pathways.
In the phase I portion of this study, researchers will determine the highest safe dose of vorinostat that can be used in children. In the phase II portion of the study, they will evaluate this dose of vorinostat in combination with etoposide.